Risk of Blood Disorders After Breast Cancer Treatment
Author Information
Author(s): Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury G J, Mehta J, Powles R, Ashley S, Kuan R, Powles T
Primary Institution: The Royal Marsden Hospital
Hypothesis
Does mitoxantrone-based therapy for breast cancer increase the risk of developing secondary myelodysplastic syndrome or acute myeloid leukaemia?
Conclusion
Mitoxantrone-based regimens significantly increase the risk of developing secondary blood disorders compared to the general population.
Supporting Evidence
- Nine patients developed MDS/AML after a median of 2.5 years.
- The crude incidence of developing MDS/AML was 15 per 100,000 patient years.
- The actuarial risk of developing MDS/AML was 1.1% at 5 years and 1.6% at 10 years.
- MTZ-based regimens carry a 10 times higher risk of MDS/AML compared to the general population.
Takeaway
If you get treated for breast cancer with a certain medicine called mitoxantrone, there's a higher chance you might get a serious blood problem later.
Methodology
Analysis of breast cancer patients treated with mitoxantrone and follow-up for the development of MDS/AML.
Limitations
The study may not account for all confounding factors influencing the development of MDS/AML.
Participant Demographics
Patients with breast cancer treated with mitoxantrone.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website